This article analyzes Utah’s state-approved pilot allowing AI to autonomously renew certain prescription medications, explaining how the program tests regulatory boundaries between administrative automation and medical judgment and why its outcomes could influence healthcare AI policy nationwide.
U.S.–India trade talks could reshape the $20B pharma export market, as new tariffs and IP disputes put generics, APIs, and vaccine supply chains under pressure.
U.S.–India pharma partnerships are evolving fast. With shifting regulations and strategic opportunities on both sides, companies must align on compliance, innovation, and collaboration to stay competitive.
As the FDA ramps up unannounced inspections at foreign drug facilities, Indian pharmaceutical manufacturers face new compliance challenges—and opportunities to lead through proactive quality assurance and audit readiness.
The Bar Council of India’s new rules allow foreign law firms to practice foreign and international law in India—but with strict limits. Co-written by Holon Law Partners’ Jashaswi Ghosh, this piece explores whether the move marks true market access or just a symbolic shift.
